Please use this identifier to cite or link to this item:
Title: The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway
Authors: Forsyth, Cecily J ;Best, O.G.;Singh, N.;Mulligan, S.P.
Issue Date: Oct-2015
Source: Volume 151, Issue 2, pp. 185 - 188
Journal title: British Journal of Haematology
Abstract: Inhibitors of heat-shockprotein 90 (Hsp90) have been proposed as a novel therapeutic option for Chronic Lymphocytic Leukaemia (CLL), particularly as their mechanism of action appears independent of mutations of ATM or TP53. We investigated the activity of a novel Hsp90 inhibitor, SNX7081, against a panel of eight haematological cell lines and 23 CLL patient samples. SNX7081 displayed significant effects on cell cycle distribution, apoptotic rate and levels of ZAP-70 in the cell lines and in the patient samples, irrespective of TP53 status. Our findings suggest SNX7081 may represent a promising therapeutic option for aggressive CLL.
DOI: 10.1111/j.1365-2141.2010.08348.x
ISSN: 0007-1048
Publicaton type: Journal Article
Keywords: Haematology
Appears in Collections:Haematology

Show full item record

Page view(s)

checked on Feb 2, 2023

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.